This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Tilt Biotherapeutics Oy. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Innovations in Cancer Therapy by Markus Vaha-Koskela
Introduction
Markus Vaha-Koskela is a prominent inventor based in Masala, Finland. He has made significant contributions to the fields of life sciences and medicine, particularly in the area of cancer therapies. His innovative work focuses on enhancing adoptive cell therapy, which has the potential to improve treatment outcomes for cancer patients.
Latest Patents
Markus Vaha-Koskela holds 1 patent for his invention titled "Enhanced adoptive cell therapy." This patent relates to the use of oncolytic adenoviral vectors, either alone or in combination with therapeutic compositions, for treating cancer in humans. The invention emphasizes the separate administration of adoptive cell therapeutic compositions and oncolytic adenoviral vectors. Additionally, it includes the development of a pharmaceutical kit and composition that utilize these vectors for therapeutic applications.
Career Highlights
Throughout his career, Markus has been dedicated to advancing cancer treatment methodologies. His work has garnered attention for its innovative approach to utilizing viral vectors in therapy, which could lead to more effective cancer treatments. He is associated with Tilt Biotherapeutics Oy, a company focused on developing novel cancer therapies.
Collaborations
Markus collaborates with notable professionals in the field, including Akseli Hemminki and Siri Tähtinen. Their combined expertise contributes to the advancement of cancer research and therapeutic strategies.
Conclusion
Markus Vaha-Koskela's contributions to cancer therapy through his patent on enhanced adoptive cell therapy highlight the importance of innovation in medical science. His work continues to pave the way for new treatment options for cancer patients.